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Abstract 
Purpose: To investigate the wound healing process via the application of mesenchymal stem cells 
(MSCs) in a mouse model. 
Methods: MSCs were collected from the bone marrow of the femur and tibia of 6 – 12-week-old 
C57BL/6 mice. Full-thickness cutaneous wounds (4 × 2 cm) were made by incision on the dorsal side of 
the mice. The wound was then subjected to one of four random treatments: phosphate-buffered saline 
(PBS) solution, 3T3 fibroblasts, naive MSCs, or interferon gamma-activated MSCs. Chalkley method 
was used to determine vascular density. A score was given, for each field examined, for CD31-positive 
areas, and the results of blind analysis were confirmed by independent analysis of a second evaluator. 
Results: The tensile strength of the wound area was significantly lower in older versus younger mice (p 
≤ 0.0007). Only one quarter of the mean force was required to disrupt wound integrity in older mice 
compared to young mice. Treatment with MSCs showed positive effects on wound healing. Activated 
MSCs showed the greatest efficacy at a dosage of 5 × 104 activated MSCs/8 cm2 of wound area or 6, 
250 cells/cm2. 
Conclusion: The results suggest that MSC therapies enhance the tissue regeneration capacity in mice, 
especially in older populations, through effective transdifferentiation into the epithelium. 
 
Keywords: Mesenchymal stem cell, wound healing, mouse 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Tissue damage, especially skin defects, remains 
a major health issue all over the world. This is 
mainly due to microbial infections, congenital 
diseases, poor conditioning, or damage 
sustained over a very large area. Numerous 
strategies have been employed to treat skin 
defects, such as the use of synthetic 
membranes, porcine xenografts, allografts, and 
permanent skin substitutes. However, these 
approaches have met with limited success. 
Typically, wound healing has three phases: 
inflammation, proliferation, and remodeling [1]. 
These stages require fibrin clot formation, cell 
migration, extracellular matrix deposition, dermal 
reconstitution, and re-epithelialization [2–5]. The 
main growth factors involved in the process of 
wound healing include the fibroblast growth 
factor (FGF) family, platelet-derived growth factor 
(PDGF), tumor necrosis factor (TNF)-α, 
epidermal growth factor (EGF), hepatocyte 
growth factor (HGF), transforming growth factor 
(TGF)-β1, and vascular endothelial growth factor 
(VEGF) [6]. Studies on the positive effects of 
exogenous growth factors on wound healing 
have failed to confirm their efficacy in clinical 
trials. 
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Mesenchymal stem cells (MSCs) are self-
renewing and can differentiate into various cell 
and tissue types, such as skin cells. Apart from 
being exogenous growth factors, MSCs have 
been shown to play important roles in the wound 
healing process, making them a promising 
candidate for cell-based therapy. The 
multipotency of MSCs has been well established 
in vitro [7–10], although there have been few in 
vivo studies. 
 
Autologous MSC-based therapy for tissue 
regeneration in older populations eliminates the 
need for extensive research on inflammatory 
responses upon usage of this therapy for tissue 
regeneration. Administration of MSCs in the 
wound region enhances regeneration by 
recruiting endothelial cells and activated 
macrophages, and also increases vascularity 
[11,12]. 
 
The functions of macrophages are greatly 
restricted in older individuals due to various 
factors, such as altered cytokine production, 
diminished expression of Toll-like receptors, and 
signaling via the ERK and MAPK pathways [13]. 
As macrophages play important roles in the 
secretion of angiogenic growth factors and 
recruitment of other molecules responsible for 
wound healing, alterations in these cells may 
hamper wound healing responses. This 
phenomenon is especially prominent in older 
populations [14]. The present study was 
performed to investigate the effects of MSCs on 
the healing of incisional wounds in both young 






Both young (6 – 12 weeks old) and aged (18 
months old) male C57BL/6 mice were obtained 
from the breeding stock of PLA General Hospital, 
Haidian District, Beijing, China. All mice were 
housed in the Department of Burn and Plastic 
Surgery vivarium (Beijing, China) under specific 
pathogen-free conditions with controlled light (12-
hour light/dark schedule; lights on 06:00 – 18:00) 
and humidity. Sterile water and food were 
provided ad libitum. Bedding consisted of wood 
shavings (aspen shavings; NEPCO, 
Warrensburg, NY). Cages were cleaned and 
sterilized every 2 weeks. The protocol of the 
animal experiment was approved by the Animal 
Care Committee of the Department of Burn and 
Plastic Surgery, Affiliated Hospital of PLA 
General Hospital (approval no. 4203441). All 
experimental procedures were conducted in 
accordance with institutional guidelines and 
conformed to the National Research Council 





Preparation and culture of MSCs were conducted 
according to established protocols [16–18]. 
MSCs were collected from the bone marrow 
(BM) of femurs and tibias of young C57BL/6 mice 
(6 – 12 weeks old). BM was flushed through a 
40-mm filter into MSC medium, which consisted 
of 10 % fetal bovine serum (Sigma Aldrich, St. 
Louis, MO), 40 % F-12 nutrients (Invitrogen, 
Carlsbad, CA), 40 % alpha-modified Eagle’s 
medium (Invitrogen), and 1 % antimycotic 
solution (Invitrogen). The cells were plated in 
MSC medium at a density of 2 × 107 per 9.6 cm2 
plate and maintained at 37 °C in a 5 % CO2 
incubator. After 72 hours of proliferation, the non-
adherent cells (non-MSCs) were removed and 
the adherent cells (MSCs) were cultured for an 
additional 7 days. Depletion of contaminating 
macrophages was carried out by 
immunomagnetic selection with biotinylated 
antibodies to CD11b (eBioscience, San Diego, 
CA), CD45 (eBioscience) and MACS anti-biotin 
beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). The negative control cell culture was 
performed at a density of 106 cells per flask. Flow 
cytometry of the isolated immune-depleted cells 
indicated < 3 % contamination with CD45+ cells. 
Thereafter, MSCs (passage 4 cells) were 
cultured with recombinant murine interferon 
gamma at 500 U/mL, administered every 3 days. 
These MSCs were stained with carboxy-
fluorescein diacetate and administered at 
specified doses. 
 
Wound healing model 
 
A total of nine mice were used in the experiments 
in each group. Using a #15 surgical blade, a 4 × 
2 cm (8 cm2) incisional wounds was created on 
the dorsal side of the C57BL/6 mice under 
anesthesia (ketamine and xylazine @ 40 mg kg-
1). The wound was than subjected to four 
treatments: phosphate-buffered saline (PBS) 
solution, 3T3 fibroblasts, naive MSCs, or 
interferon gamma-activated MSCs. The dosage 
of activated MSCs was 50,000 cells per wound. 
Following wound closure (three staples in each 
wound), the mice were treated with 
buprenorphine for postoperative analgesia. 
Macrophage depletion was performed using 
clodronate (dichloro methylene diphosphonate) 
[19]. Administration was performed 
intraperitoneally (0.2 mL) at 3-day intervals for 7 
days before opening of the wound, and 
continued until the sixth day after the operation. 
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Characterization of cell lines  
 
The experimental animals were treated with 
either enhanced green fluorescent protein 
(eGFP)-positive BM cells or MSCs (3rd – 4th 
passage) at a concentration of 106 cells/mL or 
105 cells/ml, respectively. The MSCs were 
prepared by washing and suspension in 0.8 % 
methylcellulose (Sigma Aldrich). Methylcellulose 
was used to create a semisolid environment that 
could successfully prevent cell loss from the 
wound region. The viability of cells was also 
assessed after maintenance in culture in 
methylcellulose for 7 days. Following incubation 
for 30 minutes at 4 °C, immunophenotyping of 
cells was performed using fluorescein 
isothiocyanate-conjugated antibodies against 
murine CD11b, CD29, CD31, CD44, and CD45 
(BD Pharmingen, Heidelberg, Germany). 
Fluorescence-activated cell sorting (FACS) with 
a 488 nm argon laser was used for the analyses, 
which were performed using CellQuest software 
(Becton Dickinson, San Jose, CA) for a total of at 
least 10,000 events. 
 
Analysis of vascular density 
 
Anti-CD31 antibody (BD Pharmingen) was used 
for immunohistochemical detection of blood 
vessels. Cryosections 4-mm thick, blocked with 1 
% bovine serum albumin (Sigma Aldrich) and 
preincubated with hydrogen peroxide in 
methanol, were incubated with primary antibody 
at 4 °C – 8 °C overnight. Sections were then 
incubated for 1 hour at room temperature with 
peroxidase-conjugated secondary antibody. 
Then, the samples were treated with 
diaminobenzidine (DAB)–hydrogen peroxide 
(Sigma) and counterstained with hematoxylin 
before analysis by optical microscopy. Chalkley 
method was used for the determination of 
vascular density [20]. The slides were examined 
at 250 × magnification, at a randomly distributed 
point in a specific area (0.196 mm2). The scores 
were given per field examined for CD31-positive 
areas. The results of the blinded analysis were 





Each experiment was conducted on three 
different animals concurrently and the whole 
experiment was repeated three times. 
Comparisons were performed after converting 
the tensile strength to a percentage of that in 
PBS solution-treated control animals. 
Comparison of paired samples was performed by 
Student’s paired t test, multiple group 
comparisons were performed by analysis of 
variance (ANOVA), and differences between 
groups were determined using Bonferroni’s 
method. In all analyses, p < 0.05 was taken to 




The effects of aging on tensile strength were 
determined by examining the wound tensile 
strength in both young and aged mice. The 
results showed that the wound tensile strength in 
older mice was considerably lower than that in 
young mice (p ≤ 0.0007). Compared to young 
mice (0.2 ± 0.003 N), about one quarter of the 
mean force (0.05 ± 0.002 N) was required to 
disrupt wound integrity in older mice (Figure 1). 
 
Treatment with a single dose of MSCs increased 
wound healing by about 10 % relative to the 
control group treated with PBS. However, 
activated MSCs showed the greatest efficacy (25 
% ± 2.8 % higher than controls) at a dosage of 5 
× 104 activated MSCs/8 cm2 of wound area or 6, 
250 cells/cm2. This effect was extended even up 
to day 14. This dose was lower than those 
reported in other clinical studies showing the 
effects of activated MSCs on wound healing. 
 
Upon determination of the optimal dosage, i.e., 6, 
250 cells/cm2, three separate experiments (n = 6) 
were performed for direct comparison of tensile 
strength between young and aged mice. 
Treatment of young and aged mice was 
performed simultaneously to eliminate 
differences in various parameters. Comparison of 
the results was carried out based on histological 
observation after excision of wounds on day 7. 
 
Immunohistochemistry with anti-CD31 antibody 
(Fig. 2) was performed to analyze the vascular 
density of the dermal substitute. Only a slight 
increment was detected in the MSC-treated mice 




Figure 2: Immunohistochemical analysis of the dermal 
substitute with anti-CD31 antibody to assess vascular 
density 
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Figure 1: Effect of activated mesenchymal stem cell (MSC) administration on tensile strength in incisional 
wounds in young and aged animals; (a) data are expressed as the means of three replicates; (b) aggregate data 
of the replicates normalized to control animals and expressed as the percentage change from the controls 
 
 
Figure 3: Representative fluorescence microscopy images of MSCs in incisional wounds on days 4 and 8. (A) 
Four days after the procedure, eGFP cells were seen only among the fibers of the dermal substitute. (B) On day 
8, some eGFP cells were visible in the adjacent tissue. (C) On day 4 after the procedure, eGFP-positive 
elongated MSCs were only present in the wound bed. (D) On day 8, MSCs were still predominantly seen in the 
wound bed, but had a different shape. Original magnification 100× (A) and 400× (B – D) 
 
Increase in cell number was evident for both 
bone marrow (BM) cells and MSCs in day-8 
versus day-4 samples. Four days after the 
procedure, enhanced green fluorescent protein 
(eGFP)-positive cells were seen only among the 
fibers of the dermal substitute (Figure 3A). On 
day 8, a few oval eGFP-positive cells were also 
seen in the adjacent tissue (Figure 3B). Samples 
from MSC-treated animals on day 4 after the 
procedure showed eGFP-positive elongated 
MSCs among the cells present in the wound bed 
(Figure 3C). On day 8, MSCs were still 
predominantly seen in the wound bed, but began 
to show alterations in their morphology (Figure 




Wound healing is influenced by a variety of 
factors, including wound location, personal 
history of disease, allergy, and other types of 
skin defects. There has been a great deal of 
research regarding application of various 
scaffolds, cells, and growth factors to aid and 
accelerate the process of skin regeneration [21]. 
The marked regenerative ability of the skin 
epidermis is due to the presence of epidermal 
stem cells that continuously produce 
keratinocytes. This principle has been utilized to 
develop various types of tissue-engineered skin 
grafts in clinical applications. However, the 
inability to regenerate skin appendages, such as 
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sweat glands and hair follicles, are major 
limitations. Thus, there is a need for research on 
skin grafts that complement its structural and 
functional properties [22]. MSCs have the ability 
for site-specific differentiation in response to 
cues provided by different organs. MSCs can 
differentiate not only into cells of mesenchymal 
lineage, but also into endothelium and endoderm 
cells in vitro [23]. This phenomenon suggests the 
suitability of MSCs for cutaneous wound healing. 
Therefore, we assessed the possible therapeutic 
value of MSCs in terms of promoting cutaneous 
wound healing. 
 
Under normal conditions, small amounts of 
MSCs are present in the peripheral blood 
system, which increases markedly under 
stressful conditions, such as large cuts or acute 
burns [24]. Technically, MSCs can be harvested 
with greater efficiency from the BM, where they 
are present in higher concentrations. The 
observed exponential growth of MSCs in the 
peripheral blood can be due to their release from 
the BM. The suitability of BM, rather than the 
blood system, for MSC isolation has also been 
demonstrated [25]. MSC concentration depends 
on age as well as the type and size of injury. In 
older individuals, the concentrations of MSC 
precursors are considerably reduced in both 
peripheral blood vessels and BM. Thus, we 
hypothesized that the regeneration mechanism 
could be improved in older individuals by external 
infusion of MSCs. The increased regeneration 
capability observed in older mice upon treatment 
with activated MSCs validated this hypothesis. 
We speculate that macrophage function is 
restored by MSCs, thereby improving the 
regenerative process. 
 
The tensile strength, defined as the breaking 
strength per unit thickness of tissue, is used to 
describe the healing rate of wounds and is a 
useful comparative measurement for wounds 
[26]. We investigated the impact of transplanted 
MSCs on tensile strength as a measure of the 
degree of wound healing. An optimal scar is one 
that most resembles the collagen structure, 
architecture, and tensile strength of normal skin. 
Thus, the biological status of the repaired wound 
depends on proper chemical reorganization of 
collagen fibers during the remodeling stage, 
which affects the tensile strength. The plot of 
tensile strength as a function of time has a 
characteristic exponential curve [27]. During the 
first days of the wound reparative process, the 
tensile strength increases moderately. Then, 
acceleration of the healing process occurs with a 
rapid increase in the tensile strength, which 
reaches a steady state at about 8 weeks with a 
maximum peak more than 1 year after the injury 
[27]. Any interference with the collagen synthesis 
process will be reflected in the biomechanical 
properties of the tissue, and in the wound 
recuperation period [27]. In this study, tensile 
strength was significantly greater after surgery in 
the group treated with MSCs compared with the 
control group. Although the strength of repaired 
skin incision did not reach that of uninjured skin, 
it was demonstrated previously that incisional 
skin wounds regain only 40 % of the tensile 
strength of unwounded tissue 120 days after 
wounding [27].  
 
In the present study, incisional wounds treated 
with MSCs regained almost double the strength 
compared with untreated wounds, thus validating 
our hypothesis. Experiments on healing 
excisional wounds in a human mesenchymal 
stem cell (hMSC)-populated porcine skin 
substitute showed that the wound size in nude 
rats was significantly smaller in the stem cell-
treated groups compared with controls [28]. 
Moreover, a positive role of hMSCs in limiting 
radiation-induced skin lesions (delay in lesion 
development, reduced radiation dermatitis, and 
faster healing rate) has been demonstrated [29]. 
These previous studies support our observations 





We have demonstrated the ability of activated 
MSCs to promote wound healing in acute 
incisional wounds, as reflected in regained 
tensile strength. The process is slow and further 
studies are required before human trials can be 
carried out. The significant improvement in the 
amount of tensile strength regained in the mouse 
model provides a potential approach to 
overcoming age-related barriers in healing 
capacity, and also shows the possibility of 
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